DRKS00034478已完成Unknown
Genetic Markers of Response to Newer Therapies for Type 2 Diabetes
Faculty of Medicine, University of Ljubljana0 个研究点目标入组 161 人开始时间: 2024年6月14日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 161
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- one 至 one（—）
- 性别
- All
入选标准
- •Criteria 1: previous diagnosis of type 2 diabetes mellitus
- •Criteria 2: met the inclusion criteria for treatment with newer antihyperglycaemic drugs (SGLT2 inhibitors and/or GLP-1RA inhibitors)
排除标准
- •Criteria 1: other types of diabetes mellitus
- •Criteria 2: patients with significant cognitive impairment or psychiatric disorder
- •Criteria 3: patients abusing alcohol or other drugs
- •Criteria 4: patients with cancer or a history of cancer in the last 5 years)
研究者
相似试验
招募中
不适用
Validation of novel biomarkers for treatment response to rush oral immunotherapy for food allergy in childreFood allergyJPRN-UMIN000029742Department of Clinical Research, Mie National Hospital30
招募中
不适用
Predicting the Response of Treatment in CardiomyopathyIdiopathic Dilated CardiomyopathyCardiovascular - Other cardiovascular diseasesACTRN12611000146998Professor Joseph Selvanayagam200
已完成
不适用
Age related macular degeneration pharmacogenetics studyISRCTN44202629eeds Teaching Hospitals NHS Trust (UK)350
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
Biomarkers of Response to Pembrolizumab Combined with Chemotherapy in Non-Small Cell Lung Cancer (Keynote-782)EUCTR2018-002598-22-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100